Drug Discovery Featured Articles & Applications

  1. What's Next For ADCs: How Combinations Will Help Define The Future Of Treatment 3/23/2026

    Insights gained from advancing ADC combination therapies in lung cancer are now shaping innovative approaches across multiple tumor types.

  2. 5 Takeaways From The Boston Open Science & Innovation Forum 3/20/2026

    The recent Boston Open Science & Innovation Forum was co-hosted by the Open Molecular Software Foundation (OMSF) and Ginkgo Datapoints.

  3. From "Live Drug" To Precision Tool: Redefining CAR T Safety 3/20/2026

    Through important chemistry and the right engineering, there’s new opportunity for CAR T therapeutics to target different forms of cancer with limited toxicity.

  4. NAMs In France And Europe: The Current Landscape 3/20/2026

    The EU is establishing a credible and scalable NAM ecosystem, but challenges still need to be overcome before life sciences professionals and patients can reap the benefits.

  5. Rethinking Tau Biology: The Future Of Neurodegenerative Drug Discovery 3/19/2026

    We caught up with Melissa Murray, Ph.D., and Amy Rommel, Ph.D., to discuss tau-associated neurodegenerative diseases.

  6. Proteomics Biomarkers Beyond Blood 3/16/2026

    Effective biomarker strategies have the potential to accelerate decision-making, de-risk development, and help drive precision medicine.

  7. MicroRNA Therapeutics In Metabolic Liver Disease: Context-Driven Drug Discovery 3/12/2026

    Realizing the therapeutic potential of miRNAs in liver disease requires confronting a problem the field has not fully reckoned with.

  8. Viral Coinfections: Emerging Challenges In Modern Drug Discovery 3/11/2026

    Viral coinfection is a phenomenon more complex than just the concurrency or sequential infection with multiple viruses in the same host. 

  9. Execution Debt In Early Drug Discovery: The Hidden Risk That Undermines Promising Biology 3/10/2026

    Understanding how execution debt forms, how it compounds, and how to prevent it is central to building durable discovery programs.

  10. Hope For Non-Hallucinogenic Neuroplastogens 3/9/2026

    We caught up with Joseph Tucker, Ph.D., to discuss Enveric Bioscience’s focus on developing non-hallucinogenic neuroplastogenic compounds.